Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18949105 | PARTICULATE COMPOSITION | November 2024 | January 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 18753759 | PARTICULATE COMPOSITION | June 2024 | September 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18734388 | METHODS OF TREATING ISCHEMIC STROKE AT RISK FOR CEREBRAL OR CEREBELLAR EDEMA | June 2024 | December 2024 | Allow | 6 | 1 | 1 | Yes | No |
| 18671935 | SULFONYLHYDRAZIDE DERIVATIVES AS ANTICANCER AGENTS | May 2024 | December 2024 | Allow | 7 | 0 | 1 | Yes | No |
| 18655793 | HALOGENATED PSILOCYBIN DERIVATIVES AND METHODS OF USING | May 2024 | August 2024 | Allow | 3 | 0 | 1 | Yes | No |
| 18625188 | SESQUITERPENOID DERIVATIVE AND USE THEREOF IN PREPARING BROAD-SPECTRUM ANTIVIRAL DRUG | April 2024 | October 2024 | Allow | 7 | 1 | 0 | No | No |
| 18437229 | 5-(2,4,5-TRIS(4-CHLOROPHENYL)-1H-IMIDAZOL-1-YL)PENTANOIC ACID AS AN ANTIMICROBIAL COMPOUND | February 2024 | May 2024 | Allow | 3 | 0 | 0 | No | No |
| 18409768 | PYRIMIDO[1'6':1,5]PYRAZOLO[4,3-C][1,7]NAPHTHYRIDINES AS CK2 INHIBITORS | January 2024 | July 2024 | Allow | 6 | 0 | 1 | Yes | No |
| 18391360 | USE OF L-ERGOTHIONEINE TO AMELIORATE AND PREVENT AGE-RELATED VITREOUS DEGENERATION | December 2023 | August 2024 | Allow | 8 | 1 | 0 | Yes | No |
| 18526535 | CRYSTALLINE FORM OF (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRA-HYDROPYRAZOLO[1,5-a]PYRIMIDINE-3-CARBOXAMIDE, PREPARATION, AND USES THEREOF | December 2023 | February 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18385809 | SUBSTITUTED 1,3,4-OXADIAZOLE DERIVATIVES AS ANTI-TUBERCULAR AGENTS | October 2023 | April 2024 | Allow | 6 | 2 | 0 | No | No |
| 18494734 | 5-(2,4,5-TRIS(4-CHLOROPHENYL)-1H-IMIDAZOL-1-YL)PENTANOIC ACID AS AN ANTIMICROBIAL COMPOUND | October 2023 | April 2024 | Allow | 6 | 2 | 1 | No | No |
| 18381767 | CRYSTALLINE FORM OF (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRA-HYDROPYRAZOLO[1,5-a]PYRIMIDINE-3-CARBOXAMIDE, PREPARATION, AND USES THEREOF | October 2023 | April 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18487887 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROLOGICAL DISORDERS | October 2023 | December 2023 | Allow | 2 | 0 | 0 | Yes | No |
| 18483630 | COMPOSITIONS AND METHODS FOR PROMOTING GLYCOGEN SYNTHASE ACTIVITY AND AUGMENTING GLYCOGEN STORAGE CAPABILITY | October 2023 | August 2024 | Allow | 11 | 1 | 0 | Yes | No |
| 18466547 | Methods of Treating Prostate Cancer | September 2023 | February 2024 | Allow | 5 | 1 | 0 | Yes | No |
| 18222061 | COMPOSITIONS AND METHODS FOR TREATING EPILEPSY, SEIZURES AND OTHER CONDITIONS | July 2023 | November 2023 | Allow | 4 | 1 | 0 | Yes | No |
| 18219903 | ARSINOTHRICIN AS A MULTI-STAGE ANTIMALARIAL | July 2023 | December 2023 | Allow | 5 | 1 | 0 | No | No |
| 18328397 | STORAGE STABLE AQUEOUS PARENTERAL SOLUTIONS COMPRISING DICLOFENAC | June 2023 | February 2025 | Allow | 20 | 0 | 0 | Yes | No |
| 18201938 | ANTILEISHMANIAL COMPOUNDS, COMPOSITIONS AND USE THEREOF | May 2023 | July 2024 | Allow | 14 | 2 | 1 | Yes | No |
| 18031998 | Compositions and Methods for the Prevention and Treatment of Hearing Loss | April 2023 | April 2024 | Abandon | 12 | 0 | 1 | Yes | No |
| 18130597 | STABLE ORAL SUSPENSIONS OF BACLOFEN | April 2023 | June 2023 | Allow | 3 | 0 | 0 | Yes | No |
| 18126551 | COMPOSITIONS AND METHODS FOR TREATING EPILEPSY, SEIZURES AND OTHER CONDITIONS | March 2023 | June 2023 | Allow | 3 | 0 | 0 | Yes | No |
| 18088382 | PHARMACEUTICAL FORMULATIONS OF TAFAMIDIS | December 2022 | August 2023 | Allow | 8 | 1 | 1 | No | No |
| 18087625 | STABLE ORAL SUSPENSIONS OF BACLOFEN | December 2022 | March 2023 | Allow | 3 | 0 | 0 | Yes | No |
| 18073632 | TANNIN-CONTAINING GASTROINTESTINAL FORMULATIONS AND METHODS OF USE | December 2022 | November 2024 | Allow | 23 | 0 | 0 | Yes | No |
| 17992290 | Compositions And Methods For Inhibiting Type 1 Collagen Production | November 2022 | January 2025 | Allow | 26 | 0 | 1 | Yes | No |
| 17989462 | Methods of Treating Prostate Cancer | November 2022 | July 2023 | Allow | 8 | 1 | 0 | No | No |
| 17989420 | Methods of Treating Prostate Cancer | November 2022 | July 2023 | Allow | 8 | 1 | 0 | No | No |
| 17989329 | Methods of Treating Prostate Cancer | November 2022 | July 2023 | Allow | 8 | 1 | 0 | No | No |
| 18049468 | ANTITOXINS TO BREVETOXIN | October 2022 | July 2023 | Allow | 8 | 0 | 1 | Yes | No |
| 18046919 | COMPOSITIONS AND METHODS FOR TREATING HYPERPHAGIA IN PRADER-WILLI SYNDROME | October 2022 | November 2024 | Allow | 25 | 0 | 0 | Yes | No |
| 17937215 | METHOD FOR PREVENTING PREGNANCY | September 2022 | September 2023 | Allow | 12 | 3 | 0 | No | No |
| 17934244 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | September 2022 | December 2022 | Allow | 3 | 0 | 0 | Yes | No |
| 17948882 | STABLE ORAL SUSPENSIONS OF BACLOFEN | September 2022 | December 2022 | Allow | 3 | 0 | 0 | Yes | No |
| 17944506 | COMPOSITIONS AND METHODS FOR TREATMENT OF ANTICANCER-DRUG RESISTANT CANCERS | September 2022 | December 2024 | Allow | 27 | 0 | 1 | Yes | No |
| 17941640 | PHENYLEPHRINE HYDROCHLORIDE READY-TO-USE SOLUTION | September 2022 | December 2024 | Allow | 27 | 1 | 0 | Yes | No |
| 17903080 | HALOGENATED PSILOCYBIN DERIVATIVES AND METHODS OF USING | September 2022 | January 2024 | Allow | 17 | 1 | 1 | No | No |
| 17901951 | CRYSTALLINE FORM OF (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRA-HYDROPYRAZOLO[1,5-a]PYRIMIDINE-3-CARBOXAMIDE, PREPARATION, AND USES THEREOF | September 2022 | September 2023 | Allow | 13 | 2 | 1 | Yes | No |
| 17822027 | UROLITHINS AS IMMUNE RESPONSE ENHANCERS | August 2022 | June 2024 | Allow | 22 | 0 | 0 | No | No |
| 17893105 | USE OF VDAS TO ENHANCE IMMUNOMODULATING THERAPIES AGAINST TUMORS | August 2022 | March 2025 | Abandon | 30 | 1 | 0 | Yes | No |
| 17891251 | ENHANCEMENT OF IMPAIRED MOTOR AND MENTAL FUNCTIONS, USING DEXTROMETHORPHAN AND OXIDASE ENZYME INHIBITOR | August 2022 | January 2025 | Abandon | 29 | 1 | 0 | No | No |
| 17890659 | Halogenated Xanthene Composition and Method for Treating Hematologic Cancers | August 2022 | September 2024 | Allow | 25 | 0 | 1 | Yes | No |
| 17858827 | CRYSTALLINE FORM OF (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRA-HYDROPYRAZOLO[1,5-a]PYRIMIDINE-3-CARBOXAMIDE, PREPARATION, AND USES THEREOF | July 2022 | July 2023 | Allow | 12 | 3 | 0 | Yes | No |
| 17858826 | CRYSTALLINE FORM OF (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRA-HYDROPYRAZOLO[1,5-a]PYRIMIDINE-3-CARBOXAMIDE, PREPARATION, AND USES THEREOF | July 2022 | November 2023 | Allow | 16 | 3 | 1 | Yes | No |
| 17851862 | Method of Treating Diseases of the Visual System | June 2022 | December 2023 | Allow | 17 | 2 | 0 | No | No |
| 17850050 | COMPOSITIONS AND METHODS FOR TREATING EPILEPSY, SEIZURES AND OTHER CONDITIONS | June 2022 | December 2022 | Allow | 6 | 1 | 0 | Yes | No |
| 17839147 | COMPOSITION AND METHOD FOR PREVENTING LONG-TERM COVID-19 MORBIDITY | June 2022 | November 2024 | Allow | 29 | 0 | 1 | Yes | No |
| 17837666 | AMINO ACID COMPOSITIONS FOR THE AMELIORATION OF SYMPTOMS OF ENVIRONMENTAL ENTEROPATHY | June 2022 | July 2024 | Allow | 26 | 0 | 0 | Yes | No |
| 17825773 | METHODS TO DECREASE TRIGLYCERIDE SYNTHESIS IN THE LIVER | May 2022 | November 2024 | Allow | 29 | 1 | 0 | No | No |
| 17749887 | COMPOSITIONS AND METHODS FOR TREATING DRY EYE | May 2022 | April 2024 | Allow | 23 | 0 | 0 | No | No |
| 17744369 | Polyoxometalate Complexes and Pharmaceutical Compositions | May 2022 | June 2024 | Allow | 26 | 0 | 0 | No | No |
| 17743201 | METHODS AND COMPOSITIONS FOR TREATING ECTOPARASITE INFESTATIONS | May 2022 | February 2023 | Allow | 9 | 1 | 1 | No | No |
| 17741993 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | May 2022 | December 2024 | Abandon | 32 | 1 | 0 | No | No |
| 17741427 | CRYSTALLINE FORMS | May 2022 | October 2024 | Allow | 29 | 1 | 0 | Yes | No |
| 17739648 | THERAPEUTIC USE OF LEVOROTATORY BETA-LACTAMS IN HEMATOPOIESIS, IMMUNO-ONCOLOGY THERAPY, AND REGULATION OF LIPOPROTEIN AND APOLIPOPROTEIN LEVELS | May 2022 | July 2024 | Allow | 27 | 0 | 2 | Yes | No |
| 17736257 | USE OF NOREPINEPHRINE OR BETA-ADRENERGIC RECEPTOR INHIBITOR IN PREPARATION OF MEDICAMENT FOR NERVE INJURY REPAIR IN DIABETES | May 2022 | April 2024 | Abandon | 24 | 1 | 1 | No | No |
| 17734878 | Threonate Compounds and Methods of Use Thereof | May 2022 | September 2024 | Abandon | 28 | 0 | 1 | No | No |
| 17732655 | COMPOSITIONS FOR MANAGEMENT OF POLYCYSTIC OVARY SYNDROME | April 2022 | October 2024 | Allow | 29 | 1 | 0 | Yes | No |
| 17732667 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS | April 2022 | May 2024 | Allow | 25 | 1 | 0 | Yes | No |
| 17720255 | USE OF A NITROGEN-CONTAINING BISPHOSPHONATE IN COMBINATION WITH A GLUCOCORTICOID IN PREVENTING OR TREATING VIRAL PNEUMONIA | April 2022 | May 2024 | Allow | 25 | 2 | 1 | No | No |
| 17716708 | METHODS OF REDUCING THE RISK OF CARDIOVASCULAR EVENTS IN A SUBJECT | April 2022 | October 2024 | Allow | 30 | 1 | 0 | Yes | No |
| 17716982 | COMBINATION THERAPIES WITH CBL-B INHIBITOR COMPOUNDS | April 2022 | February 2024 | Allow | 22 | 1 | 1 | Yes | No |
| 17714723 | SYNERGISTIC COMPOSITION FOR POTENTIATING STABILIZED ATP | April 2022 | September 2024 | Allow | 29 | 1 | 0 | No | No |
| 17657546 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | March 2022 | June 2022 | Allow | 3 | 0 | 0 | Yes | No |
| 17707221 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | March 2022 | July 2022 | Allow | 3 | 0 | 0 | Yes | No |
| 17692376 | Repurposing Anti-Androgen Therapy for COVID-19 and Immunotherapy | March 2022 | April 2024 | Allow | 26 | 2 | 0 | Yes | No |
| 17688222 | COMPOSITIONS AND METHODS FOR TREATING CHEMOTHERAPY RESISTANT CANCER | March 2022 | September 2024 | Allow | 30 | 1 | 0 | No | No |
| 17680817 | METHODS OF TREATING HYPERTRIGLYCERIDEMIA | February 2022 | July 2024 | Abandon | 28 | 1 | 0 | No | No |
| 17666964 | COMPOSITIONS OF HYDROXY ACIDS WITH SALICYLIC ACID AND USES THEREFORE | February 2022 | June 2024 | Allow | 28 | 2 | 1 | No | No |
| 17666201 | MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | February 2022 | April 2023 | Allow | 14 | 3 | 0 | Yes | No |
| 17591438 | STABLE ORAL SUSPENSIONS OF BACLOFEN | February 2022 | August 2022 | Allow | 6 | 1 | 0 | Yes | No |
| 17589732 | NON-INVASIVE METHOD OF TREATING COVID-19 INFECTION | January 2022 | November 2023 | Abandon | 22 | 0 | 1 | No | No |
| 17582286 | BIOMARKERS USEFUL IN THE TREATMENT OF SUBJECTS HAVING DISEASES OF THE EYE | January 2022 | May 2024 | Allow | 28 | 0 | 0 | Yes | No |
| 17577821 | METHODS OF CONTROLLING MYOCARDIAL BLOOD FLOW | January 2022 | September 2023 | Abandon | 20 | 0 | 1 | No | No |
| 17576485 | TRPV1 ACTIVATION-MODULATING COMPLEX MIXTURES OF CANNABINOIDS AND/OR TERPENES | January 2022 | November 2024 | Abandon | 34 | 1 | 0 | No | No |
| 17576075 | TERAMEPROCOL AND NORDIHYDROGUAIARETIC ACID (NDGA) DERIVATIVES AS CORONAVIRUS ANTI-VIRAL AGENTS | January 2022 | August 2023 | Allow | 19 | 1 | 1 | Yes | No |
| 17573503 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF CORONAVIRUS AND RELATED DISORDERS | January 2022 | January 2024 | Allow | 25 | 1 | 1 | Yes | No |
| 17560373 | METHODS OF TREATING MYELOPROLIFERATIVE DISORDERS | December 2021 | June 2022 | Allow | 5 | 1 | 0 | Yes | No |
| 17557987 | TITRATION OF CEBRANOPADOL | December 2021 | July 2024 | Allow | 31 | 1 | 0 | Yes | No |
| 17552967 | DICARBOXYLIC ACID ESTERS FOR THE TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH PHOSPHOLIPASE D TOXIN | December 2021 | October 2023 | Allow | 22 | 1 | 1 | Yes | No |
| 17552943 | DICARBOXYLIC ACID ESTERS FOR INDUCING AN ANALGESIC EFFECT | December 2021 | October 2023 | Allow | 22 | 1 | 1 | Yes | No |
| 17644299 | EXTERNAL USE COMPOSITION COMPRISING PAEONOL AND PANTHENOL OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS ACTIVE INGREDIENTS | December 2021 | April 2022 | Allow | 4 | 0 | 0 | Yes | No |
| 17644295 | METHODS FOR TREATING IMMUNODEFICIENCY DISEASE | December 2021 | October 2024 | Abandon | 34 | 2 | 0 | Yes | No |
| 17535103 | D9-CAFFEINE COMPOSITIONS AND USES THEREOF | November 2021 | September 2024 | Allow | 33 | 5 | 0 | No | Yes |
| 17525394 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | November 2021 | July 2024 | Allow | 32 | 1 | 0 | No | No |
| 17514390 | Therapeutic Nanomaterials | October 2021 | July 2024 | Allow | 32 | 1 | 1 | No | No |
| 17514481 | ENALAPRIL FORMULATIONS | October 2021 | October 2023 | Allow | 23 | 1 | 0 | Yes | No |
| 17604124 | ADRENALINE PHARMACEUTICAL SOLUTION FOR AN INJECTION DEVICE | October 2021 | May 2022 | Allow | 7 | 0 | 0 | No | No |
| 17501130 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HAIR LOSS | October 2021 | October 2023 | Allow | 24 | 1 | 1 | No | No |
| 17602101 | SMALL MOLECULE INHIBITORS OF GPCR GPR68 AND RELATED RECEPTORS FOR TREATING CANCER, GLIOBLASTOMA, AND OTHER INDICATIONS | October 2021 | August 2024 | Allow | 35 | 0 | 1 | Yes | No |
| 17495548 | PHENYLEPHRINE HYDROCHLORIDE READY-TO-USE SOLUTION | October 2021 | June 2022 | Allow | 8 | 1 | 0 | Yes | No |
| 17449412 | LIQUID FORMULATIONS OF INDACATEROL | September 2021 | September 2023 | Allow | 24 | 1 | 1 | No | No |
| 17488252 | PHARMACEUTICAL COMPOSITION COMPRISING FEXOFENADINE, FAMOTIDINE AND MELATONIN | September 2021 | September 2024 | Abandon | 36 | 4 | 1 | No | No |
| 17484025 | Solid Forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione | September 2021 | July 2024 | Allow | 34 | 1 | 1 | No | No |
| 17482241 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | September 2021 | November 2021 | Allow | 2 | 0 | 0 | Yes | No |
| 17479523 | COMPOSITIONS AND USES THEREOF FOR TREATMENT OF IDIOPATHIC PRETERM BIRTH | September 2021 | September 2023 | Allow | 24 | 1 | 1 | No | No |
| 17478134 | Use of Bromophenol-pyrazoline Compounds in the Treatment of Porcine Coronavirus Diseases | September 2021 | April 2023 | Allow | 19 | 0 | 1 | Yes | No |
| 17475212 | PREVENTION AND/OR TREATMENT OF CONTRAST-INDUCED ACUTE KIDNEY INJURY | September 2021 | January 2024 | Allow | 28 | 1 | 0 | No | No |
| 17472870 | COMBINATIONS OF A PYRIMIDINE CONTAINING NNRTI WITH RT INHIBITORS | September 2021 | April 2024 | Abandon | 31 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner RAO, SAVITHA M.
With a 50.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 27.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner RAO, SAVITHA M works in Art Unit 1629 and has examined 630 patent applications in our dataset. With an allowance rate of 62.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 24 months.
Examiner RAO, SAVITHA M's allowance rate of 62.5% places them in the 16% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by RAO, SAVITHA M receive 1.24 office actions before reaching final disposition. This places the examiner in the 22% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by RAO, SAVITHA M is 24 months. This places the examiner in the 70% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +49.2% benefit to allowance rate for applications examined by RAO, SAVITHA M. This interview benefit is in the 94% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 33.6% of applications are subsequently allowed. This success rate is in the 67% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 46.0% of cases where such amendments are filed. This entry rate is in the 64% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 111.1% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 78% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 73.3% of appeals filed. This is in the 57% percentile among all examiners. Of these withdrawals, 63.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 47.1% are granted (fully or in part). This grant rate is in the 54% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.2% of allowed cases (in the 48% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.5% of allowed cases (in the 50% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.